Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Exercise oscillatory ventilation (EOV) is a negative prognostic marker in patients with heart failure (HF). EOV can either disappear (D-EOV) or persist (P-EOV) during exercise, with each showing different clinical implications. The relationship between respiratory muscle weakness and EOV persistence is not well understood, and its impact on exercise performance and muscle function in HF patients needs further exploration.

Methods: This study included 98 clinically stable HF patients with reduced left ventricular ejection fraction (LVEF), all undergoing cardiopulmonary exercise testing (CPET) and measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). EOV was classified as D-EOV or P-EOV, and the temporal behavior of EOV was analyzed in relation to inspiratory muscle weakness (IMW), using standard ERS criteria.

Results: Patients with P-EOV were older, with lower BMI, showed worse exercise performance, with lower peak workload (47 [38;59] vs. 67 [52;94] watts) and pVO (10.8 [9.3;12.7] vs. 13.4 [12.1;16.0] mL/kg/min). Respiratory muscle strength was weaker in P-EOV patients (MIP: 73.3 ± 25.6 vs. 93.4 ± 26.6 cmHO; MEP: 102.9 ± 40.9 vs. 131.8 ± 40.8 cmHO). A higher proportion of P-EOV patients had IMW (p < 0.05). P-EOV patients with IMW had worse exercise capacity, lower BMI and lower exercise performance (peak workload = 41.5 [36;52] vs. 63 [46;86] watts) than those with D-EOV and IMW.

Conclusions: EOV persistence is associated with worse exercise performance, respiratory muscle weakness, and potentially sarcopenia in HF patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2025.133475DOI Listing

Publication Analysis

Top Keywords

respiratory muscle
12
temporal behavior
8
exercise oscillatory
8
oscillatory ventilation
8
patients heart
8
heart failure
8
muscle weakness
8
exercise performance
8
p-eov patients
8
patients
7

Similar Publications

Sudden Death Caused by Bilateral Diaphragmatic Eventration in Myotonic Dystrophy Type 1.

Am J Forensic Med Pathol

September 2025

Department of Pathology, St Louis University School of Medicine, Office of the Medical Examiner - City of St. Louis, St. Louis, MO.

Myotonic dystrophy type 1, or dystrophia myotonica type 1 (DM1), is a multisystem disorder inherited in an autosomal dominant manner. It is caused by a CTG tri-nucleotide expansion in the 3'-untranslated region (3'-UTR) of the dystrophia myotonia protein kinase (DMPK) gene. Core clinical features include progressive skeletal muscle weakness, myotonia, and systemic complications, with premature mortality most often due to respiratory or cardiac dysfunction.

View Article and Find Full Text PDF

Background: In patients with moderate COPD, response to pulmonary rehabilitation including exercise training varies according to the presence of peripheral muscle fatigue (pMF) of quadriceps. This study investigates the role of pMF in predicting pulmonary rehabilitation outcomes in more severe COPD patients who have already developed chronic respiratory failure (COPD-CRF).

Methods: A analysis of a prospective randomised controlled trial was performed at Istituti Clinici Scientifici Maugeri Lumezzane (Brescia, Italy), involving 30 COPD-CRF patients undergoing a pulmonary rehabilitation programme comprising 20 endurance training sessions.

View Article and Find Full Text PDF

Neuromuscular diseases are often accompanied by various types of sleep-related breathing disorders, which can exacerbate the underlying condition and are associated with a poor prognosis. Early identification is essential, and interventions such as non-invasive ventilation, oxygen therapy, and respiratory rehabilitation should be initiated promptly to mitigate disease progression and improve outcomes. Nevertheless, the rates of missed and misdiagnosed cases remain common in clinical practice.

View Article and Find Full Text PDF

Uncovering a novel role of nAChRs in oxidative stress-mediated vascular dysfunction in COPD.

Redox Biol

August 2025

Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Instituto Investigación Sanitaria-Princesa IIS-IP, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic

Tobacco smoke is the main risk factor for the development of chronic obstructive pulmonary disease (COPD). Despite current therapies alleviate symptoms there are limitations in the efficacy of treatments to curb its cardiovascular morbidities, particularly vascular dysfunction and the development of pulmonary hypertension. Our previous studies demonstrate that cigarette smoke directly contributes to pulmonary arterial dysfunction.

View Article and Find Full Text PDF